AUTH/3726/1/23 - Complainant v UCB

Alleged promotion of Fintepla (fenfluramine) on LinkedIn

  • Received
    10 January 2023
  • Case number
  • Applicable Code year
  • Completed
    04 January 2024
  • Breach Clause(s)
  • Sanctions applied
    Undertaking received
  • Additional sanctions
  • Appeal
    No appeal

Case Summary

This case was in relation to a LinkedIn post shared by a UCB employee based in Germany and liked by a senior UK employee. The post stated ‘Hope for patients with Lennox-Gastaut Syndrome!’ and included a linked article on a third party website titled ‘Epilepsia Publishes Interim Results of Open-Label Extension Study of FINTEPLA (fenfluramine) Oral Solution in Patients with Lennox-Gastaut Syndrome (LGS)’.

The outcome under the 2021 Code was:

Breach of Clause 3.2

Advertising a prescription only medicine to the public

Breach of Clause 3.6

Disguised promotion

Breach of Clause 5.1

Failing to maintain high standards

Breach of Clause 11.2

Promotion of a medicine outside the terms of its marketing authorisation

This summary is not intended to be read in isolation.
For full details, please see the full case report below.